[1]. S. Olsnes, The history of ricin, abrin and related toxins. Toxicon. 44, 361-370, 2004.
[2]. J. Audi, M. Belson, M. Patel, J. Schier, J. Osterloh, Ricin poisoning: A comprehensive review. J. Am. Med. Assoc. 294, 2342-2351,2005.
[3]. L.J. Schep, W.A. Temple, G.A. Butt, M.D. Beasley. Ricin as a weapon of mass terror-separating fact from fiction. Environ. Int. 35 1267–1271,2009.
[4]. A.M. Bramwell , J.E. Eyles, H.O. Alpar, Particulate delivery systems for biodefense subunit vaccines. Adv Drug Deliv Rev. 57, 1247-1265,2005.
[5]. J.E. Small, J.A. Richardson, S. Pincus, J. Schindler, E.S. Vitetta. Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin. Vaccine. 23, 4775-4784, 2005.
[6]. J.E. Smallshaw, J.A. Richardson, E.S .Vitetta, RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol. Vaccine. 25, 7459-7469, 2007
[[7]. P.S. Marconescu, J.E. Smallshaw, LM. Pop, S.L. Ruback, E.S. Vitetta. Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication. Vaccine. 28 5315-5322, 2010.
[8]. P.M. Legler, R.N. Brey, J.E. Smallshaw, E.S. Vitetta, C.B..Millard, Structure of RiVax: a recombinant ricin vaccine. Acta Crystallogr D Biol Crystallogr. 67 826-30, 2011.
[9]. L. Zhao, A. Seth, N. Wibowo, C.X. Zhao, N. Mitter, C. Yu, Nanoparticle vaccines. Vaccine. 32 327–337,2014.
[10]. F. Danhier, E. Ansorena, J.M. Silva, PLGA-based nanoparticles: An overview of biomedical applications. J Control Release. 161, 505–522,2012.
[12]. Kordbacheh E, Nazarian Sh, Sadeghi D, Hajizadeh A. An LTB-entrapped protein in PLGA nanoparticles preserves against enterotoxin of enterotoxigenic. Escherichia coli. Iran J Basic Med Sci. 21, 1-8, 2018.
[13]. E. Kordbacheh, S. Nazarian, A . Hajizadeh, D. Sadeghi, Entrapment of LTB protein in alginate nanoparticles protects against Enterotoxigenic Escherichia coli. APMIS. 12, 320-328, 2018.
[14]. T.E. Rajapaksa, M. Stover-Hamer, X. Fernandez, , H.A. Eckelhoefer, D.D. Lo. Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery. J Control Release. 142, 196–205,2010.
[15]. M.L. Houchin, E.M. Topp, Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms, J. Pharm. Sci. 97, 2395–2404, 2008.
[16]. D. Cun, D.K. Jensen, M.J. Maltesen, M. Bunker, High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization, Eur. J. Pharm. Biopharm. 77, 26–35,2010.
[17]. S. Freitas, H.P. Merkle, B. Gander Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology, J. Control. Release. 102, 313–332,2005.
[18]. J.U. Menon, S.Kona A.S. Wadajkar, F. Desai, A .Vadla, K.T. Nguyen. Effects of surfactants on the properties of PLGA nanoparticles. J Biomed Mater Res A. 100, 1998-2005,2012.
[19]. N. Tamilselvan, C.V. Raghavan, K. Balakumar, S. Karthik. Preparation of PLGA nanoparticles for encapsulating hydrophilic drug: modifications of standard methods and it’s in vitro biological evaluation. AJRBPS. 2, 121-132, 2014.
[20]. F. Alexis, E. Pridgen, L.K. Molnar, O.C. Farokhzad. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 5 505-15,2008.
[21]. L. Hu, H. Zhong, Zh. He. Alleviating the toxicity of quantum dots to Phanerochaete chrysosporium by sodium hydrosulfide and cysteine. Environmental Science and Pollution Research 27 (10), 11116-11126,2020.
[22]. M. Halayqa, U. Domańska, PLGA Biodegradable Nanoparticles Containing Perphenazine or Chlorpromazine Hydrochloride: Effect of Formulation and Release. Int. J. Mol. Sci. 15, 23909-23923, 2014.
[23]. S. Prabha, W.Z .Zhou, J. Panyam, V..Labhasetwar, Size dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm 244,105–15, 2004.
[24]. S.G Yang, J.E. Chang, Shin B, Park S, Na K, Shim CK. 99mTch-ematoporphyrin linked albumin nanoparticles for lung cancer targeted photodynamic therapy and imaging. J Mater Chem 2010;20:9042–6.
[25]. Zeta Potential: An Introduction in 30 Minutes.https://caliscc.org/images/presentations/Morante_Zeta_Potential.pdf. Accessed on March 31, 2014
[26]. H. Thai, C. Thuy Nguyen, L. Thi Thach et al., “Characterization of chitosan/alginate/lovastatin nanoparticles and investigation of their toxic effects in vitro and in vivo,” Scientific Reports, vol. 10, 12-25, 2020.
)
